STAT3 and hepatocellular carcinoma: More recent research has underlined the possible use of newly synthesized azaspirane derivatives, of which 2-(1-(4-(2-cyanophenyl)1-benzyl-1H-indol-3-yl)-5-(4-methoxy-phenyl)-1-oxa-3-azaspiro(5,5) undecane (CIMO) (PubChem CID:14257) was the most promising; CIMO inhibits constitutive and IL-6-induced activation of STAT3, and its inhibitory effect is specific to Tyr-705 in HCC cells, a site of STAT3 phosphorylation, making it a possible treatment for HCC [153].